Mepolizumab, marketed as Nucala, has been approved for use with other asthma medications as maintenance therapy for patients with asthma who have a history of exacerbations despite taking their current asthma treatment.
The drug is a humanized interleukin-5 antagonist monoclonal antibody produced by recombinant DNA technology in Chinese hamster ovary cells. Mepolizumab, which is given by injection every 4 weeks, reduces severe asthma attacks by reducing blood levels of eosinophils (http://1.usa.gov/20wB823).
Voelker R. Antibody Approved for Asthma. JAMA. 2015;314(23):2497. doi:10.1001/jama.2015.16802